Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

BACKGROUND: Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burden (TMB), as assessed by whole exome sequencing, correlates with improved clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciuti, Biagio, Kravets, Sasha, Dahlberg, Suzanne E., Umeton, Renato, Albayrak, Adem, Subegdjo, Safiya J., Johnson, Bruce E., Nishino, Mizuki, Sholl, Lynette M., Awad, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437848/
https://www.ncbi.nlm.nih.gov/pubmed/30922388
http://dx.doi.org/10.1186/s40425-019-0572-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437848/
https://www.ncbi.nlm.nih.gov/pubmed/30922388
http://dx.doi.org/10.1186/s40425-019-0572-6

Ejemplares similares